ÂÜÀòÂÒÂ×

Kristine Ball is an accomplished executive in the biopharmaceutical sector, currently serving as the Chief Executive Officer of Antiva Biosciences, Inc. since April 2023 and as a Board Member for Oruka Therapeutics. Ball has extensive experience on various boards, including Atreca, Inc. from 2020 to 2024, which was acquired by Immunome in May 2024, and Forty Seven Inc., which was acquired by Gilead in 2020. Previous leadership roles include Chief Executive Officer at Soteria Biotherapeutics from 2020 to 2022, and Senior Vice President of Corporate Strategy and Chief Financial Officer at Menlo Therapeutics, which merged with Vyne in 2020. Earlier career positions include Senior Vice President and Chief Financial Officer at Relypsa, which was acquired by Vifor in 2016, and KAI Pharmaceuticals, acquired by Amgen in 2012, as well as Vice President of Finance at Exelixis and Senior Manager at EY. Kristine Ball holds a degree from Babson College.